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Bio-Nano Sensium Technolo-
gies, a subsidiary of Advance
Nanotech Inc has made a signif-
icant step forward for wireless
biosensors increasingly seen as
a desirable monitoring device
for a range of chronic condi-
tions including diabetes, cardiac
conditions and asthma.
Bio-Nano Sensium Technologies
has filed for a patent on a new
technology that will automati-
cally bring imbedded biosen-
sors into conformance with
international frequency and
operating requirements.
Until now, patients with embed-
ded or worn wireless biosen-
sors had difficulty traveling
internationally. Frequency and
operating regulations differ
from nation to nation, and the
results of transmitting and
receiving wireless signals on a
prohibited spectrum range
from irritation to fatal conse-
quences for the person using
the biosensor. Bio-Nano
Sensium Technologies is a JV
between Advance Nanotech Inc
and Toumaz Technology Ltd.
Toumaz Technology Ltd is a
Imperial College, London spin-
out developer of ultra-low
power advanced semiconduc-
tors, which attracted an invest-
ment of £1.5m from Canada’s
Gennum Corporation,.
“We are advancing science and
ensuring the comfort of
patients with chronic illness,”
said Stephanie Interbartolo, SVP
of Business Development of
Advance Nanotech.
“The company has removed a
significant barrier to widspread
use of wireless devices for med-
ical applications, bringing down
costs of ownership and facilitat-
ing practical new treatments.”
This latest patent and the first
filed by Bio-Nano Sensium in
the past year in its own name is
part of a plan to add additional
patents by year’s end.
Bio-Nano Sensium also has
exclusive access to Toumaz
Technology’s patent portfolio
in the bio-nano field.
The increasing number of
patents reflects the company’s
rapid progress in its scientific
discovery process toward offer-
ing the market’s most advanced
wireless biosensors.
“The technology we are patent-
ing is a huge step forward in
our goal of developing biosen-
sor platforms that have real and
immediate impact in the treat-
ment of chronic conditions,”
said Keith Errey, CEO of Toumaz
Technology.
“We have worked diligently
over the past four years to
develop a patented, low-power
platform technology to leverage
for this kind of important com-
mercial application. It is gratify-
ing to see us come a large step
closer to realising this goal.”
Web: http://www.advance-
nanotech.com/
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